AOAmanda Leigh Olson

Amanda Leigh Olson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amanda Leigh Olson has a total of 393 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

    by Yosra M. Aljawai, Kai Cao, Jun Zou, Yudith Carmazzi, Amin Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa Khouri, Jin Im, et al.

  • Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT

    by Stella M. Davies, Emily Blyth, Catherine M. Bollard, John Craddock, Parastoo B. Dahi, David Gottlieb, Michael B. Grimley, Michael D. Keller, Ruby Khoury, Amanda L. Olson, et al.


  • Open Access

    Cultural Adaptation and Feasibility of an Inpatient Yoga Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation in Tanzania, India, and the United States: A Study Protocol

    by Smitha Mallaiah, Amanda L Olson, May Daher, Scherezade K. Mama, Santhosshi Narayanan, Nagarathna R, Raghavendra Rao, Sachin Jadhav, Nataraj Ks, Vijaya Majumdar, et al.

    Background: Cancer is a global health challenge that continues to rise worldwide. People with cancer in low- and middle-income countries (LMIC) have less access to integrative oncology programs than their counterparts in high-income countries. This is especially true of countries on the African continent, such as Tanzania. LMICs have a disproportionately higher cancer burden than their counterparts. Hematopoietic Stem Cell Transplantation (HSCT) requires extended hospitalization, including social isolation. While yoga is often recommended to help manage symptoms in oncology patients, its use has not been systematically evaluated among hospitalized patients or those undergoing HSCT. To address this gap, we designed a pilot study to culturally tailor and implement a yoga program for HSCT inpatients across diverse settings in Tanzania, India, and the United States. Methods: Five patients with hematological malignancy who underwent HSCT within the past year from each of the 3 centers will participate in semi-structured interviews to explore cultural norms, culturally appropriate language, and factors specific to yoga and psychosocial support. After any modifications to the program, 15 patients from each center will participate in the yoga program 2 weeks before HSCT and for the first 30 days after HSCT via in-person, telehealth (Zoom), or in combination. We will declare the intervention feasible if (a) at least 50% of patients complete a minimum of 6 of the 12 YT sessions and (b) at least 60% of patients complete follow-up measures at 2 months after transplant. Conclusion: This trial will provide important information regarding the cultural sensitivity and feasibility of an inpatient yoga program provided during hospitalization for 3 different centers. This data is necessary before embarking on a multicenter randomized clinical trial.

  • Open Access

    Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

    by Portia Smallbone, Kai Cao, Rima M. Saliba, Yudith Carmarzzi, Gheath Al-Atrash, Michele Alvarez, Gabriela Rondon, Warren B. Fingrut, Yosra M. Aljawai, Amanda L. Olson, et al.

    Disease progression, graft-versus-host disease (GVHD), and non-relapse mortality (NRM) are the main causes of failure after allogeneic hematopoietic cell transplantation (SCT) for myeloid neoplasms. T-cell epitope–based models classify HLA-DPB1 mismatches by permissiveness and have been associated with differential risks of GVHD, relapse, and NRM. However, most studies were conducted before the routine use of post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis for unrelated donor (UD) SCT. We retrospectively analyzed 541 adults undergoing 8/8 UD SCT with PTCy prophylaxis, categorized as DP-matched (DP-M, n = 176), permissive mismatch (DP-P, n = 219), non-permissive graft-versus-host (DP-NP-GVH, n = 82), or host-versus-graft (DP-NP-HVG, n = 64). Outcomes were compared across groups with stratification by disease risk and remission/MRD status. Two-year relapse incidence was lower with DP-P versus DP-M (18% vs 28%; HR 0.6, 95% CI 0.4–0.9, p = 0.03), most pronounced in high-risk AML/MDS, where relapse rates approached those of lower-risk disease. This effect persisted after adjustment for remission and MRD status. GVHD incidence was unaffected by DPB1 status. OS and PFS did not differ significantly; age and comorbidity were dominant predictors of NRM. In UD SCT with PTCy, DPB1-permissive mismatching reduces relapse in high-risk AML/MDS without increasing GVHD or NRM, supporting DP-P mismatching as an actionable donor-selection criterion.


  • Open Access

    Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

    by Amanda Olson, Ye Ethan Li, Rafet Basar, Pinaki Banerjee, Indresh Kaur, Glorette Abueg, Melihate Sylejmani, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva, et al.

    Background: BK virus infection is a marker of poor immune recovery, especially after kidney or allogeneic cell transplantation. Because of the challenges associated with BK virus infection and the lack of effective treatments, there is a growing interest in novel approaches, such as adoptive cellular therapy, that aim to restore antiviral immunity and promote viral clearance. Methods: Our clinical trial assessed the feasibility, safety, and efficacy of administering third‐party, BK virus‐specific cytotoxic T lymphocytes (CTLs) used to treat allogeneic HCT patients and kidney transplant patients with biopsy‐proven BK‐virus nephropathy. Comprehensive clinical assessments and correlative studies were performed. Results: The study included six patients after kidney‐transplantation and five HCT recipients. Viremia declined in most evaluable patients by Day 45 after BKCTL infusion. No new instances of graft‐versus‐host disease, kidney‐transplant rejection, graft failure, or infusion‐related toxicities were attributed to the treatment. Antiviral activity (as assessed by interferon‐γ secretion) did not differ between infused BKV‐CTLs given to kidney‐transplant versus allogeneic SCT recipients. Conclusion: In this study, we longitudinally tracked the in vivo persistence of adoptively transferred BKV‐CTLs and demonstrated their sustained functional activity. This therapy could be promising in KT and SCT patients with recent‐onset BK‐virus viremia. image


  • Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis

    by Rohtesh S. Mehta, Yosra M. Aljawai, Partow Kebriaei, Gabriela Rondon, Warren Fingrut, Portia Smallbone, Betul Oran, Amanda Olson, Richard E. Champlin, Elizabeth J. Shpall

    The prevailing fixed-hierarchy approach to donor selection for allogeneic hematopoietic cell transplantation (HCT) fails to capture critical interactions between donor age and type. We addressed this by analyzing 1713 adult recipients of matched related (MRD), matched unrelated (MUD), or haploidentical donors, receiving post-transplantation cyclophosphamide, using both regularized-Cox and XGBoost machine learning models. Our analysis revealed that the overall, independent association of donor age with survival was modest; however, its importance became pivotal within specific, context-dependent trade-offs. For example, while age-matched MRD and MUD were equivalent, a younger MUD was superior to an older MRD for elderly recipients. The survival advantage of MUD over haploidentical donors was consistent and magnified with increasing recipient age. We identified a non-linear relationship between baseline risk and the benefit of a matched versus a haploidentical donor; with the gain being maximal for intermediate-risk patients but attenuated in the highest-risk stratum. Our framework quantifies the gap that persists even between HLA-favorable haploidentical donors and matched donors. These findings provide a quantitative framework –the principles of which we have made explorable via an interactive web application –for a personalized, risk-adapted approach to donor selection. The clinical utility of this model must be confirmed in future validation studies.


  • Top Cited Papers
    Open Access

    New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma

    by Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop, Temitope Oloyede, Farrukh T. Awan, Veronika Bachanova, Talha Badar, Merav Bar, et al.

    The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P< .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T–related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.


  • Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment

    by Portia Smallbone, Mayela Mendt, Robert Sackstein, Mark R. Tanner, Indresh Kaur, Rafet Basar, Hind Rafei, May Daher, Bethany Overman, Gheath Al-Atrash, et al.

  • Top Cited Papers

    Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma

    by Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Farrukh T. Awan, Danny Luan, Veronika Bachanova, Talha Badar, Merav Bar, et al.


  • Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease

    by Curtis M. Marcoux, Amin M. Alousi, Jin Im, Laquisa C. Hill, Portia Smallbone, Uday Popat, Chitra Hosing, Partow Kebriaei, Amanda Olson, Rohtesh Mehta, et al.

    Minnesota acute graft versus host disease (AGVHD) risk score is a validated tool to stratify newly-diagnosed patients into standard-risk (SR) and high-risk (HR) groups with ~85% having SR AGVHD. We aimed to identify factors for further risk-stratification within Minnesota SR patients. A single-center, retrospective analysis of consecutive patients between 1/2010 and 12/2014 was performed. Patients who developed AGVHD within 100 days and treated with systemic corticosteroids were included (N = 416), 356 (86%) of which were Minnesota SR and 60 (14%) had HR AGVHD. Isolated upper gastrointestinal (GI) AGVHD patients had significantly better day 28 and 56 CR/PR rates (90% vs. 72%, p = 0.004) and (83% vs 66%, p = 0.01), respectively, and lower 1-year non-relapse mortality (NRM; 10% vs. 22%; HR 0.4, p = 0.03). Lower GI AGVHD had less favorable outcomes with 1-year NRM of 40% (HR 2.1, p = 0.001), although CR/PR rates were not statistically different. In multivariate analysis, lower GI involvement (HR 2.6, p < 0.001), age ≥ 50 (HR 2.9, p < 0.001) and HCT-CI > 3 (HR 2.1, p = 0.002) predicted for 1-year NRM. Heterogeneity within Minnesota SR patients requires consideration in clinical trials, as distinct outcomes are observed in those with isolated upper GI and lower GI AGVHD, highlighting the importance of stratification in clinical trial design.